Page last updated: 2024-12-11
callystatin a
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
callystatin A: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 5471086 |
CHEMBL ID | 200899 |
CHEBI ID | 80782 |
SCHEMBL ID | 16072414 |
MeSH ID | M0380045 |
Synonyms (20)
Synonym |
---|
2h-pyran-2-one,9,11,13,15-pentamethyl-12-oxo-1,3,7,9-heptadecatetraenyl)-5,6-dihydro- |
189883-16-7 |
(2r)-2-[(1e,3z,5r,7e,9e,11r,13s,14r,15s)-3-ethyl-14-hydroxy-5,9,11,13,15-pentamethyl-12-oxo-heptadeca-1,3,7,9-tetraenyl]-2,3-dihydropyran-6-one |
2h-pyran-2-one, 6-[(1e,3z,5r,7e,9e,11r,13s,14r,15s)-3-ethyl-14-hydroxy-5,9,11,13,15-pentamethyl-12-oxo-1,3,7,9-heptadecatetraenyl]-5,6-dihydro-, (6r)- |
callystatin a |
nsc-708248 |
nsc708248 |
C16891 |
CHEMBL200899 |
chebi:80782 , |
(2r)-2-[(1e,3z,5r,7e,9e,11r,13s,14r,15s)-3-ethyl-14-hydroxy-5,9,11,13,15-pentamethyl-12-oxoheptadeca-1,3,7,9-tetraenyl]-2,3-dihydropyran-6-one |
2h-pyran-2-one, 6-((1e,3z,5r,7e,9e,11r,13s,14r,15s)-3-ethyl-14-hydroxy-5,9,11,13,15-pentamethyl-12-oxo-1,3,7,9-heptadecatetraenyl)-5,6-dihydro-, (6r)- |
unii-zlk7n2r2d6 |
zlk7n2r2d6 , |
SCHEMBL16072414 |
Q5023018 |
DTXSID501029737 |
(6r)-6-((1e,3z,5r,7e,9e,11r,13s,14r,15s)-3-ethyl-14-hydroxy-5,9,11,13,15-pentamethyl-12-oxo-1,3,7,9-heptadecatetraen-1-yl)-5,6-dihydro-2h-pyran-2-one |
2h-pyran-2-one, 6-(3-ethyl-14-hydroxy-5,9,11,13,15-pentamethyl-12-oxo-1,3,7,9-heptadecatetraenyl)-5,6-dihydro-, (6r-(6r*(1e,3z,5r*,7e,9e,11r*,13s*,14r*,15s*)))- |
2h-pyran-2-one, 6-((1e,3z,5r,7e,9e,11r,13s,14r,15s)-3-ethyl-14-hydroxy-5,9,11,13,15-pentamethyl-12-oxo-1,3,7,9-heptadecatetraen-1-yl)-5,6-dihydro-, (6r)- |
Research Excerpts
Overview
Callystatin A is a prominent member of a class of natural products which display promising growth inhibition of cancer cells in their biological profile.
Excerpt | Reference | Relevance |
---|---|---|
"Callystatin A is a prominent member of a class of natural products which display promising growth inhibition of cancer cells in their biological profile. " | ( The total synthesis of (-)-callystatin A. Burzlaff, A; Chary, KP; Kalesse, M; Kasper, C; Quitschalle, M; Scheper, T, 2003) | 2.06 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
diterpenoid | Any terpenoid derived from a diterpene. The term includes compounds in which the C20 skeleton of the parent diterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups). |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (1)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID258229 | Cytotoxicity against HCT116 human colon cancer cell line | 2006 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2 | Leptostatin: a synthetic hybrid of the cytotoxic polyketides callystatin A and leptomycin B. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (21)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 18 (85.71) | 29.6817 |
2010's | 3 (14.29) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 20.30
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.30) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 21 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |